The finding strongly supports the view that the second shot should not be skipped, Stanford Medicine said in a press release. It looked at immune responses to the Pfizer vaccine, with which Stanford Medicine had begun inoculating people in December 2020. The researchers found that the first shot increases SARS-CoV-2-specific antibody levels, as expected, but not nearly as much as the second shot does. The second shot also does things the first shot doesn’t do, or barely does, the release said. “The second shot has powerful beneficial effects that far exceed those of the first shot.

Source: Indian Express July 19, 2021 19:07 UTC